Meeting
2023 ASCO Annual Meeting
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.
Authors
Joshua Z. Drago
Memorial Sloan Kettering Cancer Center, New York, NY
Joshua Z. Drago , Fresia Pareja , Komal L. Jhaveri , Elaine M. Walsh , Geoffrey Yuyat Ku , Steven Brad Maron , Yelena Y. Janjigian , Mark E. Robson , Jorge S. Reis-Filho , Shanu Modi , Pedram Razavi , Sarat Chandarlapaty
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1052)
DOI
10.1200/JCO.2023.41.16_suppl.1052
Abstract #
1052
Poster Bd #
273
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial.
First Author: Andrea Cercek
Poster
2018 ASCO Annual Meeting
International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.
First Author: Satoshi Fujii
Poster
2023 ASCO Annual Meeting
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.
First Author: Seunghwan Shin
First Author: Natália Polidorio